|Mr. Peter K. Miller||CEO & Director||778.6k||N/A||1961|
|Dr. Ramy A. Mahmoud M.D., M.P.H.||Pres & COO||609k||N/A||1965|
|Mr. Keith Alan Goldan||Chief Financial Officer||486.67k||N/A||1971|
|Mr. Michael F. Marino||Chief Legal Officer & Corp. Sec.||510.5k||N/A||1976|
|Ms. Ricci Whitlow||Sr. VP of Technical & Corp. Operations||N/A||N/A||N/A|
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
OptiNose, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 6.